Evidence map›Paper›PMID 34549821›Full record

ArticleTransfusion2021

Severe autoimmune hemolytic anemia following receipt of SARS-CoV-2 mRNA vaccine.

Sanjay R V Gadi, Patricia A R Brunker, Hanny Al-Samkari, David B Sykes, Rebecca R Saff, Janet Lo, Pavan Bendapudi, David E Leaf, Rebecca Karp Leaf

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Transfusion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. An overview of HLA variants in COVID-19 vaccine-induced autoimmunity.International journal of molecular epidemiology and genetics · 2025
    Review
  6. Aplastic Anemia Following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series.International journal of hematology-oncology and stem cell research · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Sanjay R V GadiHarvard Medical School, Boston, Massachusetts, USA.
Patricia A R BrunkerBlood Transfusion Service, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Hanny Al-SamkariDivision of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-6175-1383
David B SykesDivision of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Rebecca R SaffDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-4143-0985
Janet LoDivision of Endocrinology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pavan BendapudiBlood Transfusion Service, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
David E Leaf *Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Rebecca Karp Leaf *Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-9978-8779
Massachusetts General Hospital · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge clinical trials have demonstrated the overall safety of vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, reports have emerged of autoimmune phenomena, including vaccine-associated myocarditis, immune thrombocytopenia, and immune thrombotic thrombocytopenia. CASE PRESENTATION: Here we present a novel case of a young woman who developed life-threatening autoimmune hemolytic anemia (AIHA) after her first dose of a SARS-CoV-2 mRNA vaccine. Notably, initial direct antiglobulin testing was negative using standard anti-IgG reagents, which are "blind" to certain immunoglobulin (IgG) isotypes. Further testing using an antiglobulin reagent that detects all IgG isotypes was strongly positive and confirmed the diagnosis of AIHA. The patient required transfusion with 13 units of red blood cells, as well as treatment with corticosteroids, rituximab, mycophenolate mofetil, and immune globulin.

conclusionAs efforts to administer SARS-CoV-2 vaccines continue globally, clinicians must be aware of potential autoimmune sequelae of these therapies.

Indexed as

SARS-CoV-2Adrenal Cortex HormonesAdultAnemia, Hemolytic, AutoimmuneAutoantibodiesCOVID-19COVID-19 VaccinesErythrocyte TransfusionFemaleHumansImmunoglobulin GImmunoglobulinsMycophenolic AcidRituximabAdrenal Cortex HormonesAutoantibodiesCOVID-19 VaccinesImmunoglobulin GImmunoglobulinsMycophenolic AcidRituximabautoimmune hemolytic anemiadirect antiglobulin testSARS-CoV-2 mRNA vaccine

Identifiers

PMID34549821
PMCPMC8661722
OpenAlexW3200033182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.